- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07628023
Comparison of Cardiac Index Measurement Using Right Ventricular Pressure Curve Analysis and Thermodilution Via a Swan-Ganz IQ™ Catheter. (MICAP)
1. juni 2026 oppdatert av: Assistance Publique - Hôpitaux de Paris
Comparison of Cardiac Index Measurement by Analysis of the Right Ventricular Pressure Curve and by Thermodilution During Pulmonary Artery Catheterization Using Swan Ganz IQ™.
The pulmonary artery catheter (Swan-Ganz) is a standard tool in intensive care for measuring and monitoring cardiac index by thermodilution.
The Swan-Ganz IQ™ model also allows continuous estimation of cardiac index through analysis of the right ventricular pressure wave, which could be useful for rapidly assessing changes in cardiac output during volume expansion response tests.
However, the concordance between this continuous method and thermodilution remains poorly studied in real clinical conditions and may vary depending on certain clinical situations.
This study therefore aims to compare the cardiac index measured by thermodilution with that estimated by right ventricular pressure waveform analysis based on data collected in clinical practice.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The pulmonary artery catheter (or Swan-Ganz catheter) is a standard tool for measuring and monitoring cardiac index in intensive care.
It measures cardiac index using thermodilution, which is considered the gold standard method.
The Swan-Ganz IQ™ model also offers continuous measurement of cardiac index by analyzing the right ventricular pressure waveform.
The ability to measure cardiac output continuously would allow pulmonary artery catheterization to be used to assess cardiac output during short procedures, such as tests to predict the response to volume expansion (passive leg raising, expiratory pause), and to evaluate its effect on cardiac index.
However, the concordance between cardiac output measured by thermodilution (reference method) and that estimated by the continuous method based on analysis of the right ventricular pressure waveform remains poorly evaluated by independent data in real clinical conditions.
Furthermore, this agreement may vary depending on the clinical situation, particularly in the presence of right ventricular dysfunction, tricuspid regurgitation, or left heart failure.
In this context, this study aims to compare the cardiac index measured by thermodilution with the cardiac index estimated by analyzing the right ventricular pressure waveform, based on data collected in the clinical setting.
Studietype
Observasjonsmessig
Registrering (Antatt)
43
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Xavier MONNET, PhD
- Telefonnummer: 0145213539
- E-post: xavier.monnet@aphp.fr
Studer Kontakt Backup
- Navn: Nicolas FAGE, MD, PhD
- E-post: nicolas.fage@aphp.fr
Studiesteder
-
-
-
Angers, Frankrike, 49100
- Pierre ASFAR
-
Ta kontakt med:
- Pierre ASFAR, PhD
- E-post: piasfar@chu-angers.fr
-
Paris, Frankrike, 94000
- Xavier MONNET
-
Ta kontakt med:
- Xavier MONNET, PhD
- Telefonnummer: 0145213539
- E-post: xavier.monnet@aphp.fr
-
Ta kontakt med:
- Nicolas FAGE, MD, PhD
- E-post: nicolas.fage@aphp.fr
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Patients hospitalized in medical ICU (of Bicêtre and Angers) with pulmonary arterial catheter (PAC) place as part of routine clinical care.
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Hospitalization in intensive care
- Presence of a Swan-Ganz IQ™ pulmonary artery catheter placed as part of treatment
- Thermodilution performed by the clinician in charge as part of treatment
Exclusion Criteria:
- Pregnancy
- Legal protective measures (guardianship, conservatorship, and deprivation of liberty by court/administrative decision)
- Refusal of participation by the patient's relatives or the patient themselves.
- Cardiac output measurements by thermodilution or continuous cardiac output analysis that cannot be used.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Evaluate the concordance between cardiac index values provided according to right ventricular pressure waveform and those measured by thermodilution in patients with septic shock who are monitored by a pulmonary.
Tidsramme: 1 day
|
1 day
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the concordance between the continuous cardiac index estimated by the Swan-Ganz IQ™ catheter and the cardiac index measured by thermodilution in patients receiving vasopressor therapy, compared to patients not receiving vasopressor therapy.
Tidsramme: 1 day
|
1 day
|
|
|
Assess whether the agreement between cardiac index measured by thermodilution and that estimated by Swan-Ganz IQ™ varies across different hemodynamic profiles.
Tidsramme: 1 day
|
Investigate whether the agreement between the continuous cardiac index estimated by the Swan-Ganz IQ™ catheter and the cardiac index measured by thermodilution differs according to prespecified hemodynamic phenotypes, particularly in the presence of right ventricular dysfunction, left heart failure, and tricuspid regurgitation grade ≥ 3.
|
1 day
|
|
Assess the concordance between variations in cardiac index measured by thermodilution and those in continuous cardiac index estimated by right ventricular pressure wave analysis, before and after volume expansion performed as part of treatment.
Tidsramme: 1 day
|
1 day
|
|
|
Assess the consistency of changes in cardiac output before and after volume expansion, depending on the use of vasopressors.
Tidsramme: 1 day
|
Assess the concordance between changes in cardiac index measured by thermodilution and those estimated by right ventricular pressure wave analysis before and after volume expansion, depending on the presence or absence of vasopressor treatment at the time of measurement.
|
1 day
|
|
Assess the agreement between changes in cardiac output measured by thermodilution and those estimated continuously by analysis of the right ventricular pressure wave, before and after a change in the dose of norepinephrine.
Tidsramme: 1 day
|
Evaluate the concordance between variations in cardiac index measured by thermodilution and those of continuous cardiac index estimated by right ventricular pressure wave analysis, before and after a change in norepinephrine dose administered as part of treatment.
|
1 day
|
|
Determine the least significant change (LSC) in the continuous cardiac index estimated by the Swan-Ganz IQ™ catheter, based on the observed measurement variability.
Tidsramme: 1 day
|
1 day
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Studieleder: Xavier MONNET, PhD, Assistance Publique - Hôpitaux de Paris
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
10. juni 2026
Primær fullføring (Antatt)
10. juni 2028
Studiet fullført (Antatt)
10. juni 2028
Datoer for studieregistrering
Først innsendt
1. juni 2026
Først innsendt som oppfylte QC-kriteriene
1. juni 2026
Først lagt ut (Faktiske)
4. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
4. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. juni 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Infeksjoner
- Sepsis
- Systemisk inflammatorisk responssyndrom
- Betennelse
- Sjokk
- Patologiske tilstander, tegn og symptomer
- Sjokk, septisk
- Undersøkelsesteknikker
- Terapeutikk
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Kateterisering
- Endovaskulære prosedyrer
- Vaskulære kirurgiske inngrep
- Kardiovaskulære kirurgiske inngrep
- Minimalt invasive kirurgiske inngrep
- Diagnostiske teknikker, kardiovaskulær
- Hjertefunksjonstester
- Hjertekateterisering
- Catheterization, Peripheral
- Catheterization, Swan-Ganz
Andre studie-ID-numre
- APHP260231
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .